Arteriovenous Fistula Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major arteriovenous fistula markets reached a value of US$ 253.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 412.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.53% during 2024-2034.
The arteriovenous fistula market has been comprehensively analyzed in IMARC's new report titled "Arteriovenous Fistula Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arteriovenous fistula is a medical condition that occurs due to an abnormal connection between a vein and an artery, disrupting the natural blood flow pattern within the circulatory system. This direct link causes arterial blood to flow directly into a vein without first passing through the capillaries, leading to a range of signs and symptoms. The indications of an arteriovenous fistula can vary depending on its location and size. Common signs include localized swelling, a pulsating mass, and a prominent blue or purplish appearance of the affected area. Additionally, patients might experience pain, throbbing sensations, and high risk of bleeding due to the increased pressure of arterial blood in the venous system. Diagnosing an arteriovenous fistula typically involves a combination of physical examination, medical history review, and imaging techniques. Doppler ultrasound, magnetic resonance angiography (MRA), and computed tomography angiography (CTA) are commonly used to visualize the abnormal connection and assess its size and impact on blood circulation.
The rising incidences of trauma or injuries that can cause a direct connection between an artery and a nearby vein, bypassing the normal capillary network, are primarily driving the arteriovenous fistula market. In addition to this, the inflating utilization of surgical and endovascular methods, since they ensure the optimal flow of blood between arteries and veins, thereby preserving the quality and viability of capillaries in individuals suffering from the illness, is also creating a positive outlook for the market. Moreover, the widespread adoption of comprehensive medical care and therapeutic approaches, encompassing rehabilitative measures and patient education, is further bolstering the market growth. These procedures focus on boosting physical and mental well-being, optimizing functional abilities, and enhancing the overall quality of life. Apart from this, the rising usage of effective medical techniques, including percutaneous transluminal angioplasty, on account of their numerous benefits, like shorter recovery times, immediate improvement in blood flow, and reduced risk of complications as compared to traditional open surgeries, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine and tissue engineering strategies, which focus on developing biological substitutes to rejuvenate or replace damaged tissues, is expected to drive the arteriovenous fistula market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the arteriovenous fistula market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for arteriovenous fistula and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arteriovenous fistula market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the arteriovenous fistula market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the arteriovenous fistula market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current arteriovenous fistula marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the arteriovenous fistula market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the arteriovenous fistula market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the arteriovenous fistula market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of arteriovenous fistula across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of arteriovenous fistula by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of arteriovenous fistula by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with arteriovenous fistula across the seven major markets?
What is the size of the arteriovenous fistula patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of arteriovenous fistula?
What will be the growth rate of patients across the seven major markets?
Arteriovenous Fistula: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for arteriovenous fistula drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arteriovenous fistula market?
What are the key regulatory events related to the arteriovenous fistula market?
What is the structure of clinical trial landscape by status related to the arteriovenous fistula market?
What is the structure of clinical trial landscape by phase related to the arteriovenous fistula market?
What is the structure of clinical trial landscape by route of administration related to the arteriovenous fistula market?
The arteriovenous fistula market has been comprehensively analyzed in IMARC's new report titled "Arteriovenous Fistula Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arteriovenous fistula is a medical condition that occurs due to an abnormal connection between a vein and an artery, disrupting the natural blood flow pattern within the circulatory system. This direct link causes arterial blood to flow directly into a vein without first passing through the capillaries, leading to a range of signs and symptoms. The indications of an arteriovenous fistula can vary depending on its location and size. Common signs include localized swelling, a pulsating mass, and a prominent blue or purplish appearance of the affected area. Additionally, patients might experience pain, throbbing sensations, and high risk of bleeding due to the increased pressure of arterial blood in the venous system. Diagnosing an arteriovenous fistula typically involves a combination of physical examination, medical history review, and imaging techniques. Doppler ultrasound, magnetic resonance angiography (MRA), and computed tomography angiography (CTA) are commonly used to visualize the abnormal connection and assess its size and impact on blood circulation.
The rising incidences of trauma or injuries that can cause a direct connection between an artery and a nearby vein, bypassing the normal capillary network, are primarily driving the arteriovenous fistula market. In addition to this, the inflating utilization of surgical and endovascular methods, since they ensure the optimal flow of blood between arteries and veins, thereby preserving the quality and viability of capillaries in individuals suffering from the illness, is also creating a positive outlook for the market. Moreover, the widespread adoption of comprehensive medical care and therapeutic approaches, encompassing rehabilitative measures and patient education, is further bolstering the market growth. These procedures focus on boosting physical and mental well-being, optimizing functional abilities, and enhancing the overall quality of life. Apart from this, the rising usage of effective medical techniques, including percutaneous transluminal angioplasty, on account of their numerous benefits, like shorter recovery times, immediate improvement in blood flow, and reduced risk of complications as compared to traditional open surgeries, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine and tissue engineering strategies, which focus on developing biological substitutes to rejuvenate or replace damaged tissues, is expected to drive the arteriovenous fistula market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the arteriovenous fistula market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for arteriovenous fistula and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arteriovenous fistula market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the arteriovenous fistula market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the arteriovenous fistula market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current arteriovenous fistula marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the arteriovenous fistula market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the arteriovenous fistula market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the arteriovenous fistula market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of arteriovenous fistula across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of arteriovenous fistula by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of arteriovenous fistula by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with arteriovenous fistula across the seven major markets?
What is the size of the arteriovenous fistula patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of arteriovenous fistula?
What will be the growth rate of patients across the seven major markets?
Arteriovenous Fistula: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for arteriovenous fistula drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arteriovenous fistula market?
What are the key regulatory events related to the arteriovenous fistula market?
What is the structure of clinical trial landscape by status related to the arteriovenous fistula market?
What is the structure of clinical trial landscape by phase related to the arteriovenous fistula market?
What is the structure of clinical trial landscape by route of administration related to the arteriovenous fistula market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARTERIOVENOUS FISTULA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ARTERIOVENOUS FISTULA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARTERIOVENOUS FISTULA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ARTERIOVENOUS FISTULA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARTERIOVENOUS FISTULA - UNMET NEEDS
10 ARTERIOVENOUS FISTULA - KEY ENDPOINTS OF TREATMENT
11 ARTERIOVENOUS FISTULA - MARKETED PRODUCTS
11.1 List of Arteriovenous Fistula Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ARTERIOVENOUS FISTULA - PIPELINE DRUGS
12.1 List of Arteriovenous Fistula Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ARTERIOVENOUS FISTULA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARTERIOVENOUS FISTULA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARTERIOVENOUS FISTULA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Arteriovenous Fistula - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Arteriovenous Fistula - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Arteriovenous Fistula - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Arteriovenous Fistula - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Arteriovenous Fistula - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Arteriovenous Fistula - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Arteriovenous Fistula - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Arteriovenous Fistula - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Arteriovenous Fistula - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Arteriovenous Fistula - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Arteriovenous Fistula - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Arteriovenous Fistula - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Arteriovenous Fistula - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Arteriovenous Fistula - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Arteriovenous Fistula - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Arteriovenous Fistula - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Arteriovenous Fistula - Access and Reimbursement Overview
16 ARTERIOVENOUS FISTULA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARTERIOVENOUS FISTULA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARTERIOVENOUS FISTULA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARTERIOVENOUS FISTULA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ARTERIOVENOUS FISTULA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARTERIOVENOUS FISTULA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ARTERIOVENOUS FISTULA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARTERIOVENOUS FISTULA - UNMET NEEDS
10 ARTERIOVENOUS FISTULA - KEY ENDPOINTS OF TREATMENT
11 ARTERIOVENOUS FISTULA - MARKETED PRODUCTS
11.1 List of Arteriovenous Fistula Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ARTERIOVENOUS FISTULA - PIPELINE DRUGS
12.1 List of Arteriovenous Fistula Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ARTERIOVENOUS FISTULA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARTERIOVENOUS FISTULA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARTERIOVENOUS FISTULA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Arteriovenous Fistula - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Arteriovenous Fistula - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Arteriovenous Fistula - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Arteriovenous Fistula - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Arteriovenous Fistula - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Arteriovenous Fistula - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Arteriovenous Fistula - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Arteriovenous Fistula - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Arteriovenous Fistula - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Arteriovenous Fistula - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Arteriovenous Fistula - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Arteriovenous Fistula - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Arteriovenous Fistula - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Arteriovenous Fistula - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Arteriovenous Fistula - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Arteriovenous Fistula - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Arteriovenous Fistula - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Arteriovenous Fistula - Access and Reimbursement Overview
16 ARTERIOVENOUS FISTULA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARTERIOVENOUS FISTULA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARTERIOVENOUS FISTULA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
